These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37974944)

  • 1. Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
    Sabnis RW
    ACS Med Chem Lett; 2023 Nov; 14(11):1491-1492. PubMed ID: 37974944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
    Sabnis RW
    ACS Med Chem Lett; 2022 Aug; 13(8):1217-1218. PubMed ID: 35978687
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
    Sabnis RW
    ACS Med Chem Lett; 2022 Jun; 13(6):883-884. PubMed ID: 35707157
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
    Sabnis RW
    ACS Med Chem Lett; 2022 Apr; 13(4):528-529. PubMed ID: 35450363
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.
    Abdel-Magid AF
    ACS Med Chem Lett; 2023 Feb; 14(2):129-130. PubMed ID: 36793429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.
    Bhatwadekar AD; Kansara VS; Ciulla TA
    Expert Opin Investig Drugs; 2020 Mar; 29(3):237-244. PubMed ID: 31985300
    [No Abstract]   [Full Text] [Related]  

  • 7. Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
    Teufel DP; Bennett G; Harrison H; van Rietschoten K; Pavan S; Stace C; Le Floch F; Van Bergen T; Vermassen E; Barbeaux P; Hu TT; Feyen JHM; Vanhove M
    J Med Chem; 2018 Apr; 61(7):2823-2836. PubMed ID: 29517911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma kallikrein and diabetic macular edema.
    Feener EP
    Curr Diab Rep; 2010 Aug; 10(4):270-5. PubMed ID: 20535647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches.
    Abdulaal M; Haddad NM; Sun JK; Silva PS
    Semin Ophthalmol; 2016; 31(1-2):19-24. PubMed ID: 26959125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade.
    Busse P; Kaplan A
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):716-722. PubMed ID: 34838707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma kallikrein and prorenin in patients with hereditary angioedema.
    Purdon AD; Schapira M; De Agostini A; Colman RW
    J Lab Clin Med; 1985 Jun; 105(6):694-9. PubMed ID: 3889200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema.
    Abdel-Magid AF
    ACS Med Chem Lett; 2017 Aug; 8(8):776-777. PubMed ID: 28835783
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma kallikrein-kinin system and diabetic retinopathy.
    Liu J; Feener EP
    Biol Chem; 2013 Mar; 394(3):319-28. PubMed ID: 23362193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
    Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute macular edema and peripapillary soft exudate after pancreas transplantation with accelerated progression of diabetic retinopathy.
    Tsai FY; Lau LI; Li AF; Chen SJ; Wang SE; Lee FL; Liu CJ; Shyr YM
    J Chin Med Assoc; 2017 May; 80(5):319-325. PubMed ID: 28330678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy.
    Chung YR; Park SW; Choi SY; Kim SW; Moon KY; Kim JH; Lee K
    Cardiovasc Diabetol; 2017 Jan; 16(1):4. PubMed ID: 28061854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Aygören-Pürsün E; Zanichelli A; Cohn DM; Cancian M; Hakl R; Kinaciyan T; Magerl M; Martinez-Saguer I; Stobiecki M; Farkas H; Kiani-Alikhan S; Grivcheva-Panovska V; Bernstein JA; Li HH; Longhurst HJ; Audhya PK; Smith MD; Yea CM; Maetzel A; Lee DK; Feener EP; Gower R; Lumry WR; Banerji A; Riedl MA; Maurer M
    Lancet; 2023 Feb; 401(10375):458-469. PubMed ID: 36774155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
    Riedl MA; Aygören-Pürsün E; Baker J; Farkas H; Anderson J; Bernstein JA; Bouillet L; Busse P; Manning M; Magerl M; Gompels M; Huissoon AP; Longhurst H; Lumry W; Ritchie B; Shapiro R; Soteres D; Banerji A; Cancian M; Johnston DT; Craig TJ; Launay D; Li HH; Liebhaber M; Nickel T; Offenberger J; Rae W; Schrijvers R; Triggiani M; Wedner HJ; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan WP; Maurer M
    Allergy; 2018 Sep; 73(9):1871-1880. PubMed ID: 29688579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Lipids and Proliferative Diabetic Retinopathy and Macular Edema in Persons With Long-term Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy.
    Klein BE; Myers CE; Howard KP; Klein R
    JAMA Ophthalmol; 2015 May; 133(5):503-10. PubMed ID: 25502808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?
    Gunay BO; Erdogan G; Akalin I; Kalkisim A; Esenulku CM; Gunay M
    Arq Bras Oftalmol; 2023; 87(6):e20220228. PubMed ID: 37878875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.